COMPANY PROFILE

Mynosys Cellular Devices

Explore full profile

Mynosys Cellular Devices is a global ophthalmic technology company

San Francisco, United StatesFounded 2006Biotech & Life Sciences

Valuation $100–250M Last recorded · 2019

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Mynosys Cellular Devices

Zepto Cataract is a pioneering company in the ophthalmic technology sector, specializing in advanced solutions for cataract surgery. The company’s core product automates the anterior capsulotomy process, aligning it precisely on the visual axis of the eye using patient fixation during surgery. This technology not only increases edge strength but also ensures precise, repeatable, and circular capsulotomies, which are crucial for the effective overlap of the intraocular lens (IOL) optic. Zepto's solutions are designed to be more cost-effective than femtosecond laser-assisted cataract surgery (FLACS) while maintaining the surgical workflow without disruption.

Zepto primarily serves ophthalmic surgeons and medical institutions that perform cataract surgeries. Operating in the global ophthalmic technology market, the company leverages a business model that focuses on selling its advanced surgical devices and related services. Revenue is generated through the direct sale of these devices, as well as through ongoing customer support and training services.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2006
Headquarters: San Francisco, United States
Employees: 13
Open positions: None listed
Dealroom signal: 24.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Oct 2019	$25M	$100M	Decheng Capital	—
SERIES BEquity / VC	Mar 2016	$4M	$16M	Visionary Ventures	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Mynosys Cellular Devices website traffic

Latest recorded traffic for Mynosys Cellular Devices is 40 monthly website visits. Mynosys Cellular Devices's team declined 31.6% over the past year.

Latest monthly visits40 1-year team growth-31.6%

Monthly website visitsJan 2020–Apr 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LSLife SI3D bioprinters and microfluidics systems for healthcare	Argentina	Operational	6	$112K	$200K
TBTrestle BiotherapeuticsBioengineered kidney tissues to restore renal function and reduce dialysis dependency	San Diego, United States	Operational
LULuceroA Swedish biotech start-up that creates precision liquid handling solutions that help pharmaceutical companies use 3D cell cultures at scale	Göteborgs Stad, Sweden	Operational
BIBioMindBioMind is developed in collaboration with the world's largest hospital for neurological diseases	Singapore, Singapore	Operational
UNUniteLabsThe digital infrastructure for a new generation of biotech	Munich, Germany	Operational
PRPredxBioTissue-Based Decision Intelligence for Oncology	Bellevue, United States	Operational
CECellbricksBiofabricated human tissue therapeutics for organ regeneration.	Berlin, Germany	Operational
NANanocarrierMedical products by applying the micellar nanoparticle technology	Chiba, Japan	Operational